MedTrace Logo

Lerapolturev in Recurrent Malignant Glioma

NCT02986178 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2025-07-11

Study results available
· View outcomes & findings →

Summary

This is a phase 2 study of lerapolturev, an oncolytic polio/rhinovirus recombinant, in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma.

Conditions

  • Malignant Glioma

Interventions

BIOLOGICAL

lerapolturev

A single dose of lerapolturev, an oncolytic polio/rhinovirus recombinant

DRUG

Lomustine

one cycle of oral lomustine

Sponsors & Collaborators

Principal Investigators

  • Head of Clinical Operations · Istari Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2022-09-30
Completion
2023-02-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02986178 on ClinicalTrials.gov